BDSI remains committed to the chronic pain community during the COVID-19 pandemic. For more
information on access to our products, please call our customer service line at 1-800-469-0261.

NEWS: BDSI Completes Acquisition of ELYXYB Learn More >
PARTNERSHIPS

Business Development Opportunities

Working together to improve the lives of patients living with serious and debilitating chronic conditions.

BDSI actively seeks partnerships and product licenses in the areas of neurology, pain, psychiatry, and select rare diseases. We collaborate in ways that expand and strengthen the process of commercializing innovative therapies, and are open to working within a variety of mutually beneficial deal structures.

Working With BDSI

For more information on the growing BDSI portfolio, or to explore partnership opportunities, please contact Kevin Ostrander.

Kevin Ostrander, SVP, Business Development 4131 Parklake Avenue, Suite 225 Raleigh, NC 27612 Tel: 919-582-9050

Asterisks denote required fields

Recent BDSI News

November 3, 2021

Total Net Revenue of $41.1 Million , an Increase of 4% versus Prior Year Strong profitability with GAAP EPS of $0.07 , EBITDA Margin of 27% and $7.0 million Operating Cash Flow Closed acquisition of ELYXYB, the first FDA-approved, ready-to-use oral solution for acute migraine with potential

Read more
October 21, 2021

RALEIGH, N.C. , Oct. 21, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International , Inc. (NASDAQ: BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions, today announced the appointment of John Golubieski as Chief Financial

Read more
October 20, 2021

RALEIGH, N.C. , Oct. 20, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with chronic conditions, announced today that it will report its third quarter 2021 financial results before the open of

Read more
More news

Upcoming Events

There are no events to display

Stay Connected

Stay up to date on the latest news

Get started now
November 29, 2021BDSI $2.82/ - -3.09%
Data provided by Nasdaq. Minimum 15 minutes delayed.